Caricamento...
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 14% of all lung cancer diagnoses. Despite decades of active research, treatment options for SCLC are limited and resistance to the few Food and Drug Administration (FDA) approved therapies develops rapidly. With no approved...
Salvato in:
| Pubblicato in: | Transl Lung Cancer Res |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5835589/ https://ncbi.nlm.nih.gov/pubmed/29535912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.02.03 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|